PBH
NYSE · Pharmaceuticals
Prestige Consumer Healthcare
$47.73
+0.93 (+1.99%)
Financial Highlights (FY 2026)
Revenue
1.09B
Net Income
191.22M
Gross Margin
54.7%
Profit Margin
17.5%
Rev Growth
-1.2%
D/E Ratio
0.54
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 54.7% | 54.7% | 54.1% | 54.1% |
| Operating Margin | 28.4% | 25.6% | 32.4% | 26.3% |
| Profit Margin | 17.5% | 16.6% | 30.0% | 31.3% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 1.09B | 1.11B | 462.83M | 441.46M |
| Gross Profit | 598.50M | 605.59M | 250.19M | 238.64M |
| Operating Income | 310.90M | 283.12M | 150.18M | 116.02M |
| Net Income | 191.22M | 174.13M | 138.88M | 138.12M |
| Gross Margin | 54.7% | 54.7% | 54.1% | 54.1% |
| Operating Margin | 28.4% | 25.6% | 32.4% | 26.3% |
| Profit Margin | 17.5% | 16.6% | 30.0% | 31.3% |
| Rev Growth | -1.2% | -1.2% | +15.0% | +3.5% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 385.56M | 385.56M | 1.29B | 1.07B |
| Total Equity | 715.19M | 715.19M | 1.56B | 1.69B |
| D/E Ratio | 0.54 | 0.54 | 0.82 | 0.63 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 331.94M | 319.08M | 217.92M | 202.17M |
| Free Cash Flow | — | — | 109.94M | 68.20M |